VentriPoint Diagnostics Ltd V.VPT

With Huhg and Bart initiates 👀GranhamB sad manipulator

[jopatclo]

For GranhamB see remember  with Huhg and Bart initiates( Insiders buy on the one market for one reason, they think its going up Insiders know!)why you are a manipulator Granhamb.

For new people who watch Ventripoint (ATTENTION GranhamB. Sad character to have several fake accounts to denigrate Ventripoint and Dr. Adams with this technology that saves lives, they are vultures.)

Hugh MacNaughtHugh MacNaught • Following • FollowingPresident and CEO at Ventripoint Diagnostics Ltd.President and CEO at Ventripoint Diagnostics Ltd.1mo • 1 month ago

 

Great points Bart. Faster, less expensive and providing cMRI levels of accuracy make VMS+ a compelling option for clinical trials, particularly those monitoring right ventricle volumes and ejection fractions. AI enhanced echo is a more patient-friendly modality which improves patient recuitment and compliance thereby improving efficiency and reducing risk.

Bart HendriksBart Hendriks • Following • FollowingMotivational Speaker, CEO, Mentor, and Strategic Advisor in start- and scale-ups, with expertise in pioneering clinical AI applications and cutting-edge technology.Motivational Speaker, CEO, Mentor, and Strategic Advisor in start- and scale-ups, with expertise in pioneering clinical AI applications and cutting-edge technology.1mo • 1 month ago

Revolutionizing Cardiac Diagnostics: The Cost-Effective and Inclusive Power of Ventripoint VMS+ Over Traditional MRI in Clinical Trials

In the realm of cardiac diagnostics, the Ventripoint VMS+ system emerges as a transformative tool, offering a unique blend of efficiency, cost-effectiveness, and patient inclusivity. Here’s why researchers and clinicians are opting for VMS+ over traditional cardiac MRI:

High Precision with Lower Costs: Traditional cardiac MRIs are known for their steep costs, encompassing expensive imaging equipment, specialized facilities, and prolonged testing times. In contrast, the Ventripoint VMS+ leverages standard echocardiography equipment to provide MRI-equivalent heart measurements, significantly reducing costs and making it a financially viable option for extensive clinical trials.

Enhanced Efficiency: The lengthy process required for MRI scans often leads to increased trial durations and higher costs. VMS+ simplifies cardiac assessment, enabling rapid, on-the-spot evaluations and accelerating the trial process.

Improved Patient Experience: The daunting nature of MRI scans can deter patient participation. The non-invasive and patient-friendly approach of the VMS+ increases comfort and compliance, which is crucial for successful clinical trials.

Magnetless Technology: The VMS+ system utilizes magnetless technology, making it a safe option for patients with pacemakers or other metallic implants who are typically excluded from MRI studies. This inclusion broadens the potential patient population for clinical trials, enhancing the diversity and applicability of research findings.

Reliable Data Collection: VMS+'s advanced algorithms deliver consistent and repeatable cardiac measurements, providing robust and reliable data essential for precise clinical analysis.

Dramatic Cost Reductions: Clinical trials can achieve significant cost reductions by integrating the VMS+ system. The savings come not only from eliminating expensive MRI scans but also from reduced patient attrition and more efficient data collection processes.

Accessibility and Portability: The VMS+'s portable nature expands its usability across diverse clinical settings, further driving down logistical costs and facilitating broader geographic reach in trials.

In clinical trials, where managing costs without compromising quality is paramount, the Ventripoint VMS+ offers an innovative, cost-effective, and inclusive solution. Connect with us to explore how VMS+ is reshaping cardiac diagnostics, making advanced technology accessible and affordable for a wider range of patients!

hashtag#Ventripoint hashtag#ClinicalTrials hashtag#CardiacHealth hashtag#Innovation hashtag#MedicalDevices hashtag#Cardiology hashtag#PacemakerSafe hashtag#CRO

[jopatclo]

Pandora we know your agenda of denigrating Ventripoint. For those new to Ventripoint, see all the FUD messages from Pandora . Dude, no shares with Ventripoint. FDA V4.0 or clinics buy ? Insiders know! Bart likes this Tim Leiner, Bart Hendriks I think of very good reasons to like this Insiders buy on the one market for one reason, they think its going up Insiders know! news anytime now

[beenthere]

So? Doesn't  change the fact what he wrote about the patent is the truth. He is entitled to his own opinion  of  what it means to moving the patent forward. For sure since you have lived this stock for years and know everything about VPT why don't you give your faithful followers your opinion  about this instead of running down posters just because you don't

[Pandora]

Hey Jopat, did I say something incorrect about the patent progress? It is straight off the USPTO site. The inventor, Desmond Hirson, has been trying since April 2020 toget the Examiner at the USPTO to give a clearance for the probe. It has been "rejected" once in 2021, once in 2022, twice in 2023, and now once in 2024. It is a very tough field. There must be hundreds of 'probes'

[jopatclo]

Interesting comment  Scott H.Scott H. • 3rd+ • 3rd+IT Category ManagerIT Category Manager1mo • Edited • 1 month ago Follow   Ventripoint ($VPTDF on the OTC) is only $.16/share today. Definitely going to be a game changer. Invest now! Don't say I didn't tell you. Go check them out, do some research and

[jopatclo]

Insiders know! news anytime now   Go to Dr. Adams the visionary for FDA V4.0 or Sales? Last shake.shake for this game to scare small investors relax    FDA V4.0 and sales at any time now    

[jopatclo]

Interesting https://cdn-ceo-ca.s3.amazonaws.com/1huppni-GEHealthcare_Ventripoint_Intel_Briefing_20230208%20-%20Copy.pdf The Ventripoint – GE Partnership Though details of the partnership have been kept under wraps, it is possible to make inferences about how the relationship came to be – and perhaps the significance of it - based on the academics who have studied the VMS+ and direct

[jopatclo]

Positive for the end of the week, interesting to see.

[beenthere]

Positive? Did you look at the top of this page? NEGATIVE   -.01.